Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT05886816
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Mitoquinone/mitoquinol mesylate — DRUG
    Mitochondrial antioxidant
  • Placebo — OTHER
    Placebo pills

Study Details

Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection.

Key Dates

Start date
Mar 1, 2024
Status verified
Mar 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
112 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Mito-MES
    MitoQ pills 20 mg orally daily taken during the study and initiated within 3 days post exposure.
  • Placebo Comparator: Control group
    Placebo pills orally daily taken during the study and initiated within 3 days post exposure.

Primary Outcome Measure

SARS-CoV-2 infection [ Time Frame: Within 14 days after exposure to SARS-CoV-2 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Southwestern Medical CenterDallasTexas75219
Theodoros Kelesidis, MD, PhD, Msc
[email protected]
214-648-3486

Find similar trials in Dallas, TX

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
University of Texas Southwestern Medical Center· Dallas, TX

Related Studies